# Mosunetuzumab in Combination With Pirtobrutinib in Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia (MPOWER)

> **NCT07548450** · PHASE2 · NOT_YET_RECRUITING · sponsor: **University of Utah** · enrollment: 25 (estimated)

## Conditions studied

- Waldenstrom Macroglobulinemia

## Interventions

- **DRUG:** Pirtobrutinib
- **DRUG:** Mosunetuzumab

## Key facts

- **NCT ID:** NCT07548450
- **Lead sponsor:** University of Utah
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06
- **Primary completion:** 2034-06
- **Final completion:** 2035-06
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2026-04-23

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07548450

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07548450, "Mosunetuzumab in Combination With Pirtobrutinib in Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia (MPOWER)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07548450. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*